Johnson & Johnson (JNJ) Stake Decreased by Mcrae Capital Management Inc.

Mcrae Capital Management Inc. lessened its stake in Johnson & Johnson (NYSE:JNJ) by 3.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,784 shares of the company’s stock after selling 1,093 shares during the period. Johnson & Johnson accounts for about 1.6% of Mcrae Capital Management Inc.’s portfolio, making the stock its 24th largest position. Mcrae Capital Management Inc.’s holdings in Johnson & Johnson were worth $3,612,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Jaffetilchin Investment Partners LLC boosted its stake in Johnson & Johnson by 21.4% in the 1st quarter. Jaffetilchin Investment Partners LLC now owns 3,792 shares of the company’s stock worth $472,000 after purchasing an additional 669 shares in the last quarter. State of Tennessee Treasury Department boosted its stake in Johnson & Johnson by 23.0% in the 1st quarter. State of Tennessee Treasury Department now owns 2,072,592 shares of the company’s stock worth $258,142,000 after purchasing an additional 387,937 shares in the last quarter. CIBC World Markets Inc. boosted its stake in Johnson & Johnson by 111.8% in the 1st quarter. CIBC World Markets Inc. now owns 948,655 shares of the company’s stock worth $118,155,000 after purchasing an additional 500,662 shares in the last quarter. Blue Chip Partners Inc. boosted its stake in Johnson & Johnson by 1.2% in the 1st quarter. Blue Chip Partners Inc. now owns 62,939 shares of the company’s stock worth $7,839,000 after purchasing an additional 749 shares in the last quarter. Finally, Holderness Investments Co. boosted its stake in Johnson & Johnson by 69.9% in the 1st quarter. Holderness Investments Co. now owns 25,371 shares of the company’s stock worth $3,160,000 after purchasing an additional 10,436 shares in the last quarter. Institutional investors and hedge funds own 65.70% of the company’s stock.

Shares of Johnson & Johnson (NYSE JNJ) opened at $139.72 on Monday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 12 month low of $110.76 and a 12 month high of $144.35. The company has a market cap of $375,360.59, a P/E ratio of 24.26, a price-to-earnings-growth ratio of 2.84 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. During the same period in the previous year, the business posted $1.68 EPS. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. equities research analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.40%. The ex-dividend date was Monday, November 27th. Johnson & Johnson’s payout ratio is 58.33%.

A number of analysts recently commented on the stock. Piper Jaffray Companies reiterated a “hold” rating and issued a $120.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 4th. Vetr cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price for the company. in a research note on Monday, September 18th. Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a research note on Wednesday, October 18th. Wells Fargo & Co upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $140.00 to $149.00 in a research note on Monday, October 9th. Finally, BMO Capital Markets lifted their target price on shares of Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 12th. Four equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $145.52.

WARNING: This article was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.com-unik.info/2018/01/01/johnson-johnson-jnj-stake-decreased-by-mcrae-capital-management-inc.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit